Jiangxi Boya Biopharmaceutical Co., Ltd., formerly known as Jiangxi Boya Biopharmaceutical Co., Ltd., founded in 1993, is a comprehensive medical industry group focusing on blood products and integrating biochemical drugs, chemical drugs, API and so on. Headquartered in Fuzhou City, Jiangxi Province. The company successfully landed on the growth Enterprise Market of Shenzhen Stock Exchange of China (stock code: 300294) in March 2012. The company is mainly engaged in the research and development, production and sales of blood products. The company’s main products are albumin, immunoglobulin and coagulation factor 3 categories, 7 varieties and 21 specifications. It is one of the most complete production enterprises of albumin and intravenous immunoglobulin in China, and it is also one of the few enterprises with complete three types of products in the country. Corporate Honor: won the Forbes Chinese version of China’s top 100 potential listed companies in 2013, 2014 and 2016, the top 50 Chinese listed companies on the gem in 2014, and the top 100 listed companies most respected by investors in 2015. honors such as Taurus, one of the top 150 listed companies in 2016, and the top 10 most valuable pharmaceutical companies in 2017.